The Cancer Vaccine That Could Save Moderna
Summary
The Journal examines Moderna’s pivot from its pandemic-era COVID vaccine success to a promising new cancer treatment. Despite a 90% stock drop and financial struggles, the company’s mRNA melanoma vaccine showed strong results in preventing cancer recurrence. This breakthrough, developed with Merck, signals a major strategic shift toward oncology and offers hope for Moderna’s future viability.
Topics discussed
Moderna's stock crash and surprising cancer vaccine breakthrough
Moderna's origins and early hesitation to target cancer
Internal debate: Realists vs. Dreamers on oncology
Seed funding and partnership with Merck
Pandemic pivot, financial boom, and post-COVID slump
Promising Phase 2 and 3 trial results for melanoma
FDA approval hopes and future of mRNA oncology
New 'My Monday Morning' series and show credits
Listen ad-free on Castria